Semaglutide Slows Aging Markers in HIV Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Semaglutide slowed biological aging markers in a randomized, placebo-controlled trial of 108 adults with HIV-associated lipohypertrophy, published in Nature Communications by UC San Diego's Michael Corley and colleagues.
- Participants on semaglutide showed a 9% slower pace of biological aging on the DunedinPACE epigenetic clock and significant slowing on PCGrimAge, which tracks age-related disease and all-cause mortality risk.
- Effects spanned multiple clocks tied to inflammation and the health of blood, brain, heart, kidneys, liver, and metabolism—not just a single measure.
- A companion pilot study in npj Aging of semaglutide in HIV patients with fatty liver disease found 42% had slower aging on DunedinPACE, 34% on PCGrimAge, and roughly 49% showed longer telomeres and faster walking speed.
- Corley attributes the effect to reduced chronic inflammation and visceral/ectopic fat, adding that emerging data suggest GLP-1 drugs may "reprogram certain cells in different organs."
- Researchers stress semaglutide is not an anti-aging drug and that much larger trials are needed to confirm results, determine duration of benefit, and identify which patients benefit most.
- The Stein Institute for Research on Aging plans to build personalized "aging dashboards" from epigenetic clocks to monitor biological aging and tailor treatments.
Why it matters: For the millions already taking Ozempic and Wegovy primarily for weight loss or diabetes, this is the first placebo-controlled human signal that semaglutide may also dial back epigenetic aging clocks—but the evidence comes from a small HIV-specific cohort (n=108) and the lead author explicitly says it does not yet justify anti-aging claims.
